GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Cefiderocol (Fetroja)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

UCSF - cefiderocol and effluent-specific continuous therapy

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

CRRT effluent guidance is not an intermittent-HD dose table

The selected official and mirror tables agree. Their CRRT guidance is explicitly initial and depends on effluent rather than a CrCl band.

What to reconcile: Confirm modality and L/hour effluent, then reassess residual function and clinical status; do not interpolate a new algorithm.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references

The recovered institutional page has different printed boundaries

The official label uses CrCl >=120; UCSF prints >120 beside 60-119. The upper effluent band is >=4.1 L/hour in the label versus >4 in UCSF.

What to reconcile: For exactly CrCl 120 the official label is explicit. Preserve the institutional discrepancy and seek clarification for effluent values between printed bands; do not interpolate. This is a wording/boundary comparison, not evidence of different clinical outcomes.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Professional

UCSF - cefiderocol and effluent-specific continuous therapy

Open original reference

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

All doses are IV over 3 hours. CrCl >120 mL/min: 2 g every 6 hours; 60-119: 2 g every 8 hours; 30-59: 1.5 g every 8 hours; 15-29: 1 g every 8 hours; <15: 750 mg every 12 hours. The source omits exactly 120.

Intermittent HD: 750 mg every 12 hours. Continuous-therapy effluent <=2 L/hour: 1.5 g every 12 hours; 2.1-3: 2 g every 12 hours; 3.1-4: 1.5 g every 8 hours; >4: 2 g every 8 hours. Intermediate decimal flow values not assigned by these printed ranges need clarification. These flow-specific regimens supersede a generic low-CrCl row for the relevant modality.

RDM30-040-cefiderocol-1 · Source locator: UCSF - cefiderocol and effluent-specific continuous therapy; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/cefiderocol
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
e2b65d51046c014daafb528d446162e63e3cfad8e04dc0d588e9312425bf6b14

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=cefiderocol&s1=RDM30-040-cefiderocol&h1=1aa06fb4953f400c99150a2aa168f972fa9467c0348852822f26c3ffbdc52479